FAS controls warning execution by the Ministry of Health Care of the Russian Federation

| By | FAS Russia, Medicinal Drug Prices, Ministry of Health Care
0
2029

Under enforcement of compliance with the antimonopoly law, the Federal Antimonopoly Service (FAS Russia) asks pharmaceutical manufacturers, who consider that their rights on executing Clause 6(1) of the Rules for keeping the Register of medicinal drug prices [1] were infringed, to re-file their statements to the Ministry of Health Care of the Russian Federation and copies – to FAS.

At the end of 2016, FAS warned the Ministry of Health Care of the Russian Federation to eliminate signs of unreasonably obstructing operations of pharmaceutical companies.

Executing the warning, the Ministry was supposed to restore the rights of all applicants who had been unreasonably refused to enter changes to the Register records on medicine prices under Clause 6(1) of the Rules for keeping the Register of medicine prices. The period for executing the warnings is extended till 31st January 2017.

For the purposes of the Ministry of Health Care executing the warning and restoring legitimacy, FAS asks pharmaceutical companies, who believe that their rights were infringed due to refusals by the Ministry of Health Care to make the relevant changes to the Register records on drug prices under any grounds specified in Clause 6(1) of the Rules for keeping the Register of medicine prices, to re-file their complaints to the Ministry of Health Care of the Russian Federation and copies to the Federal Antimonopoly Service by 31 January 2017.

[1] Clause 6(1) of the Rules for keeping the State Register of maximum ex-works manufacturer prices for medicinal drugs included in the list of vital and essential drugs, approved by No. 865 Decree of the Government of the Russian Federation of 29.10.2010.

SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.